Replies to post #5994 on Revance Therapeutics Inc (RVNC)

[soma2022]

you keep repeating the same stuff Emmanow. Foley lowered pricing, fired old marketing team and President Sjuts. He now allows price advertising.

he has addressed all your concerns and has changed messaging. what would you change from his current course if you were CEO for a month.

my only issue is his ask for accounts to price daxi at half the price of Botox on a unit basis. This pricing will dramatically drop the profit margins to the Injector/practice. doxy should be priced at 25 to 33% lower than Botox on a unit basis. Not 50% lower on a unit basis. pricing it like Mark Foley is recommending is not sustainable as it harms the profits for practices.

most large savvy accounts I keep in contact with that are gaining traction are pricing daxi at 25 to 33% below Botox on a per unit basis. patients save money, profit per treatment is higher than botox for the practice and Revance gets increasing sales and marketshare. all three have to win in order for Daxi Sales to thrive and grow in the coming years.